Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).
Human intravenous immunoglobulins (IVIg) contain natural autoantibodies against the inhibitory lectin-receptors Siglec-8 and Siglec-9. These two members of the Siglec family are known to mediate both inhibitory and death signals. Here, we discuss recent findings regarding the cytotoxic effects of natural anti-Siglec autoantibodies on both neutrophils and eosinophils, and present the concept of a novel regulatory mechanism exhibiting anti-inflammatory properties. Consequently, IVIg may amplify this regulatory pathway by increasing the concentration of natural anti-Siglec autoantibodies in blood and tissues.
von Gunten
Stephan
S
Institute of Pathology, University Hospital Basel, Basel, Switzerland. sgunten@yahoo.com
Simon
Hans-Uwe
HU
D015703:Antigens, CD / Q000276:immunology* / Q000502:physiology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology* / Q000502:physiology; D001323:Autoantibodies / Q000276:immunology / Q000633:toxicity*; D004804:Eosinophils / Q000187:drug effects; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000633:toxicity*; D037102:Lectins / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000502:physiology; D009504:Neutrophils / Q000187:drug effects; D063265:Sialic Acid Binding Immunoglobulin-like Lectins
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D037102:Lectins; C403967:SIGLEC8 protein, human; C412227:SIGLEC9 protein, human; D063265:Sialic Acid Binding Immunoglobulin-like Lectins